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Abstract. It was established that patients with pyoder-
matosis had changes in indicators of cellular and humeral 
immune system with manifestations of secondary immuno-
deficiency state in T-cell link. It was revealed the relation-
ship between the nature of changes of systemic immunity 
and clinical course of pyodermatosis which justifies a dif-
ferentiated administration of immunocorrecting drugs to 
such patients.  
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Introduction. Pyodermas are a group of pustul-
ar skin diseases caused by pyogenic cocci 
(staphylococci, streptococci and others) [1, 3, 10]. A 
high incidence of pyodermas, a tendency to chronici-
ty, frequent development of deep forms with stable 
scarring of the skin is the cause of psycho-emotional 
disorders in patients, reducing their ability to work 
and social activity that generally defines an import-
ant medical and social significance of pyoderma and 
justifies the relevance of research with a study of 
pathogenetic factors of pyococcus skin lesions to 
improve their treatment and prevention [2, 8, 9]. 
 It has been established by today that the pat-
hogenesis of pyoderma is a complex, multifactorial, 
and the changes of immune reactivity of the organ-
ism play an important role [1-3, 7]. However, inf-
ormation on the immune system in these patients are 
often ambiguous and contradictory - they register as 
a manifestation of increased immune activity and the 
formation of secondary immunodeficiency state, 
which may contribute to chronic dermatoses piokok-
ovyh and their resistance to standard therapy tools 
[4, 7-9]. In this regard, the urgent task of modern 
dermatology is to establish the nature of changes of 
systemic immunity in patients with pyoderma with 
different clinical course in order to clarify the pat-
hogenetic factors and develop differentiated methods 
of treatment.  
Objective. To determine and analyze the values 
of the systemic immunity in patients, suffering from 
pyodermias with their different clinical course 
Material and methods. 128 patients with 
pyodermias aged from 18 to 69 among which 74 
men (57,8 %) and 54 women (42,2 %) were ob-
served. They had been concluded into the study ac-
cording to the following criteria: clinical signs of 
primary pyodermia, patients’ age which was more 
than 18 years old, absence of chronic somatic disease 
or their exacerbations when the patient was being 
examined. According to the clinical criteria [1, 3], 69 
(53,9 %) patients were diagnosed with staphylode-
rma, 40 of them had superficial forms
(osteofolliculitis, folliculitis, sycosis vulgaris while 
29 of the patients had deep forms (boils, hydradeni-
tis) 36 (28,1 %) were diagnosed with streptococcal 
impetigo, 20 of them had superficial forms 
(streptococcal impetigo itself) and 16 –deep ones 
(ecthyma), 23 (18,0 %) had mixed pyodermias, 14 of 
which with superficial forms (vulgar impetigo) and 9 
patients had deep ones(chronic ulcerous pyodermia). 
In 44 (34.4 %) patients pustular skin process oc-
curred for the first time, in 84 (65,6 %) it had a chr-
onic course. The control group were 34 practically 
healthy persons (donors) of the same age.  
For the assessment of systemic immunity in 
patients with pyoderma, we determined: total and 
relative number of T-lymphocytes (CD3 +), T-helper 
(CD4 +) and T-suppressor lymphocytes (CD8 +), 
immunoregulatory index - IRI (CD 4 + / CD 8+), the 
number of B lymphocytes (CD19 +) by indirect 
immunofluorescence using monoclonal antibodies to 
cell surface antigens and serum of (Ig) immunoglob-
ulins of class M, G, A according to the known met-
hod [6]. Statistical analysis of the results of research 
was carried out by the methods of statistical analysis 
[5] using the computer program Statistica 6.0, the 
probable average difference was considered at 
p<0,05.  
Results of the study and discussion. While 
determining the indicators of the systemic immunity 
in 128 patients with pyodermias we established their 
probable (р<0,001) changes, compared with the indi-
cators with patients in the control group: decrease in 
relative and absolute number of total lymphocytes 
pool – by 20,4 % (28,9±0,69%, in the control group 
– 36,3±0,91 %) and 21,2 % (1,90±0,051 cal/ml in the 
control group – 2,41±0,10 cal/ml), T lymphocytes – 
by 19,2 % (47,1±1,33 %, in the control group – 
58,3±1,09 %) and 33,7 % (0,955±0,033 cal/ml in the 
control group – 1,44±0,082 cal/ml), T-helper lym-
phocyte subpopulations – according to 11,7 % 
(33,1±0,34 %, in the control group – 37,5±0,91 %) 
and in 22,9 % (0,613±0,022 cal/ ml in the control 
group – 0,796±0,054 cal/ ml), and the relative num-
ber of T-suppressor lymphocytes – by 13,9 % 
(18,5±0,15 %, in the control group – 21,5±0,93 %) 
against the backdrop of increasing relative and abso-
lute number of B lymphocytes – by 14,3 % 
(25,6±0,30 %, in the control group – 22,4±0,81 %) 
and 35,2 % (0,488±0,014 cal/mkl in the control 
group – 0,360±0,020 cal/ml) and IgM levels – by 
25,7 % (1,81±0,047 g/l in the control group – 
1,44±0,06 g/l) and IgG – to 40,4 % (13,3±0,25 g/l in 
the control group – 9,49±0,34 g/l).  
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Notes: 1. * – Differences in the degree of probability compared to the control group: * – р<0,05; ** – p<0,01; *** – p<0,001. 
2. p1-2, p1-3, p2-4 – Differences in the probability of different groups of patients 
The analysis of systemic immunity in patients 
with pyoderma depending on clinical form and depth 
of skin lesions, which are presented in the table, sho-
wed that in patients with superficial pyoderma it was 
only noted a moderate, compared to the control gro-
up, relative decrease in the number of total lympho-
cyte pool (with surface streptoderma - to 10,5 %, 
p<0,05, in staphilodermias - by 13,7 %, p<0,01), 
reducing the relative and absolute number of T cells 
(with superficial streptodermas – 8,5 % and 21,5 %, 
p<0,01, in staphilodermias - by 7,5 %, p<0,001 and 
20,1 %, p<0,01, with mixed pyodermas - by 12,0 %, 
p<0,001 and 18 7 %, p<0,05), the relative number of 
T-helper cells (with superficial streptodermas – by 
9,9 %, p<0,001, while with staphilodermas by 
6,24 % and combined with pyodermas – by 8,1 %, 
p<0,05) and the absolute number of B-lymphocytes 
(with superficial streptoderma – 29,4 % staphilode-
rmas – by 35,7 %, combined pyoderma – by  
47,4 %, p<0,001).  
However, patients with deep pyoderma forms 
had experienced significant changes in all monitored 
parameters and systemic humoral immunity as com-
pared to the control group indices and indicators as 
compared to patients with superficial pyoderma for-
m. Thus, in patients with deep pyoderma there was 
likely (p<0,001) decrease in absolute and relative 
number of common pool of lymphocytes compared 
to the control group performance (respectively with 
deep streptoderma – 32,8 % and 48,5 %, with deep 
staphilodermas – 34,4 % and 46,5 %, combined with 
deep pyoderma – by 47,4 % and 34,4 %) and patients 
with corresponding indicators of superficial forms of 
pyoderma (compared to superficial streptodermas – 
by 24,9 % and 39,2 %, staphilodermas – 34,4 % and 
40,8 %, combined pyoderma –- by 39,2 % and  
28,8 %). The patients with deep pyoderma also ex-
perienced a significant reduction of the relative and 
absolute number of T-lymphocytes compared to the 
performance of the control group (respectively in 
deep streptoderma – 24,4 % and 62,1 %, with staphi-
lodermas – 15,8 % and 34,7 % with combined pyo-
derma – 28,9 % and 54,6 %, p<0,001) and patients 
with corresponding indicators of superficial forms of 
pyoderma (compared to the superficial streptodermas 
– by 17,3 % and 51,7 %, p<0,001, staphilodermas – 
by 8,9 %, p<0,05 and 17,6 %, p<0,01 and superficial 
combined pyoderma – 19,5 % and 44,1 %, p<0,001. 
In patients with deep pyoderma forms the relative 
and absolute number of T-helper lymphocytes also 
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reduced compared with the control group (the deep 
streptoderma – 27,2 % and 57,4 %, p<0,001 and 
staphilodermas – by 17,3 %, p<0,001 and 21,9 %, 
p<0,01; in deep combined pyoderma – 33,3 % and 
49,9 %, p<0,001) and relevant groups of patients 
with superficial pyoderma superficial streptoderma – 
19,0 % and 46,6 % for staphilodermas – by 13,2 % 
and 19,1 % for combined superficial pyoderma – 
26,9 % and 47,5 %, p<0,001). 
At the same time, in patients with deep pyoder-
ma the relative number of T-suppressors reduced 
compared to the control group indicators (with deep 
streptoderma – by 21,9 %, p<0,05, with deep staphi-
lodermas – 16,3 % and deep pyoderma combined – 
by 23,6 %, p<0,01), as well as the relative and absol-
ute number of T-suppressors compared with patients, 
having corresponding superficial pyoderma 
(concerning patients with superficial streptoderma – 
by 13,8 % and 47,9 % and combined pyoderma – by 
8,8 % and 35,8 %, p<0,001).  
The analysis of the humoral immune system in 
patients with different clinical forms of pyoderma 
showed a significant,as compared to the control gro-
up,increase in the absolute number of B-lymphocytes 
in patients with deep streptoderma (respectively by 
14,3 %, p<0,05 and 32,4 %, p<0,001), staphiloderma 
(22,7 % and 52,4 %, p<0,001) and combined pyoder-
ma (37,1 % and 34,3 %, p<0,001), and the increase 
in the relative number of lymphocytes compared 
with groups of patients with corresponding clinical 
forms of pyoderma (as compared to superficial strep-
todermas – by 10,9 %, p<0,01, staphilodermas – 
23,2 % and combined pyoderma – by 28,5 %, 
p<0,001) without probable differences between the 
absolute values of B lymphocytes. In addition, the 
patients with deep pyoderma had probable increase 
of IgM and IgG as compared to indices of the control 
group (respectively in deep streptoderma – by 
45,8 % and 63,3 %, deep staphiloderma – by 54,2 % 
and 68,6 % of deep pyoderma combined – by 96,5 % 
and 90,72 % p<0,001), and patients with superficial 
pyoderma (on superficial streptoderma – by 37,3 % 
and 45,8 %, superficial staphilodermas – 42,3 % and 
32,0 %, superficial pyoderma combined – by 48,5 % 
and 52,2 %, p<0,001).  
The analysis of systemic immunity in patients 
with different clinical forms of pyoderma 
(staphiloderma, streptoderma, combined) with super-
ficial skin lesions didn’t find significant differences 
in these patients except the relative number of T-
helper cells, which, in patients with superficial staph-
iloderma, was slightly higher than that of patients 
with superficial streptoderma (by 9,9 %, p<0,05) and 
combined pyoderma (by 19,4 %, p<0,001). At the 
same time, there were no significant differences in 
most studied parameters of the systemic immunity 
between patients with deep pyoderma depending on 
the etiological factor, only in case of combined pyo-
derma there was probable decrease of the relative 
number of lymphocytes compared with the rate of 
patients with deep streptoderma (by 21,7 %, 
p<0,001), decrease in relative and absolute number 
of T-lymphocytes compared with indicators of patie-
nts with deep streptoderma (respectively, 6,1 % and 
19,8 %, p<0,05) and deep staphiloderma 
(respectively: by 15,7 %, p<0,001 and by 31,0 %, 
p<0,01), reducing the relative and absolute number 
of T-helper cells compared to figures of patients with 
deep streptoderma (respectively: by 8,2 %, p<0,01 
and 17,7 %, p<0,05) and staphiloderma (19,4 % and 
35,9 %, p<0,001). In patients with deep combined 
pyoderma there was also a significant increase com-
pared to patients with deep strepto-staphiloderma 
and relative number of B-lymphocytes (respectively 
20,1 % and 11,8 %, p<0,001), and the level of IgM 
(34,8 % and 27,5 %, p<0,001) and IgG (16,8 % and 
13,1 %, p<0,001).  
Consequently, most of the patients with pyoder-
ma had varying degrees of changes in rates of syste-
mic immunity – the likely reduction in relative and 
absolute number of total lymphocytes, T lymphocy-
tes and their subpopulations against the growing 
number of B lymphocytes and the level of IgM and 
IgG, which generally indicates the formation in these 
patients secondary immunodeficiency state of T link 
on the background of activation of humoral immuni-
ty in response to the development of pyococcus skin 
inflammation. The most significant changes in rates 
of systemic immunity with the depletion of T-cell 
immunity were found in patients with deep pyoder-
ma forms, especially in deep combined pyoderma 
with prolonged chronic course, with no significant 
differences in immune parameters depending on the 
etiological factor of pyoderma (streptoderma, staphi-
loderma) justifying differentiated administration of 
immunomotropic drugs for such patients.  
Conclusion  
In patients with pyoderma,changes in systemic 
immunity indexes that indicate the formation of sec-
ondary immunodeficiency state T-cell link, amid an 
adequate humoral immunity have been found. It was 
established that there is a relationship between the 
nature of changes of systemic immunity and clinical 
course of pyoderma justifying differentiated admini-
stration of the immunocarrective drugs to such pa-
tients.  
Prospects for further research. Prospects for 
further research is the development and evaluation of 
integrated treatment of various forms of pyoderma 
with differentiated administration of immunocorre-
ctive treatment, considering the systemic immunity 
of the patients.  
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ПОКАЗАТЕЛИ СИСТЕМНОГО ИММУНИТЕТА У БОЛЬНЫХ ПИОДЕРМИЯМИ  
С РАЗНЫМ КЛИНИЧЕСКИМ ТЕЧЕНИЕМ  
М.О. Дашко1, О.И. Денисенко2  
Резюме. Установлено, что у больных пиодермиями имеют место изменения показателей клеточного и гумора-
льного системного иммунитета с проявлениями вторичного иммуннодефицитного состояния по Т-клеточному зве-
ну. Выявлено наличие взаимосвязи между характером изменений показателей системного иммунитета и особенно-
стями клинического течения пиодермий, что обосновывает дифференцированное назначение таким пациентам им-
муннокорригирующих препаратов. 
Ключевые слова: пиодермии, клиническое течение, системный иммунитет. 
ПОКАЗНИКИ СИСТЕМНОГО ІМУНІТЕТУ У ХВОРИХ НА ПІОДЕРМІЇ  
З РІЗНИМ КЛІНІЧНИМ ПЕРЕБІГОМ  
М.О. Дашко1, О.І. Денисенко2  
Резюме. Встановлено, що у хворих на піодермії мають місце зміни показників клітинного й гуморального 
системного імунітету з проявами вторинного імунодефіцитного стану за Т-клітинною ланкою. Виявлено наявність 
взаємозв’язку між характером змін показників системного імунітету та особливостями клінічного перебігу піодер-
мій, що обґрунтовує диференційоване призначення таким пацієнтам імунокоригуючих засобів. 
Ключові слова: піодермії, клінічний перебіг, системний імунітет. 
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